Solange Peters, MD, PhD, Highlights Practicing Changing Research From the 2021 ESMO Annual Congress

Video

Solange Peters, MD, PhD, detailed several important abstracts from the Presidential Symposia at the 2021 ESMO Congress she believes will be practice changing.

CancerNetwork spoke with Solange Peters, MD, PhD, head of the medical oncology service and chair of thoracic oncology in the Oncology Department at the Centre Hospitalier Universitaire Vaudois and president of the European Society for Medical Oncology (ESMO), about some of the potentially practice changing abstracts that were presented during the2021 European Society of Medical Oncology Congress. Peters highlight the importance of the phase 3 IMpower010 trial (NCT02486718), which examined the use of adjuvant atezolizumab (Tecentriq) in patients with non–small cell lung cancer, as well as the phase 2 FIRSTMAPP trial, which examined the use of sunitinib (Sutent) in pheochromocytoma and paraganglioma compared with placebo.

Transcription:

After tomorrow, we have the additional detailed presentation about adjuvant atezolizumab in lung cancer in IMpower010.1 It has been previously presented, but it's good because this presentation will tell us who the are patients who have to receive adjuvant atezolizumab; [it will] really go into the subgroups. We also have an amazing trial, which is the first randomized trial in a super rare disease entity, which is malignant progressive pheochromocytoma and paraganglioma, which [was treated with] sunitinib versus placebo.2 [It’s] really amazing to do a trial in such a rare entity. We [also] have 2 abstracts about SARS-CoV-2 immunity—1 about the vaccine and 1 about immunity—on Monday, which are very important for our patient community. All of these abstracts, altogether 11 abstracts through 3 presidential symposia, will change the practice.

References

  1. Felip E, et al. IMpower010: Patterns of relapse and subsequent therapy from a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in stage IB-IIIA non-small cell lung cancer (NSCLC). Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. Abstract LBA9.
  2. Baudin E, Goichot B, Berruti A, et al. First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): An academic double-blind trial investigating sunitinib. Annals of Oncology. 2021;32(suppl_5): S621-S625. doi:10.1016/annonc/annonc700.
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.